Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma

Respiratory Medicine

Volumn 103, Issue 3, 2009, Pages 342-347

  Lu, Susan ^a   Liu, Nancy ^a   Dass, S Balachandra ^a   Reiss, Theodore F ^a   Knorr, Barbara A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; FEV1; Phosphodiesterase 4 inhibitor

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MK 0359; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LOOSE FECES; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; VOMITING;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ASTHMA; CHRONIC DISEASE; CROSS-OVER STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; PEAK EXPIRATORY FLOW RATE; PHOSPHODIESTERASE INHIBITORS; SAMPLE SIZE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59349115144     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.10.024     Document Type: Article

References (18)

1. Gillissen A. Managing asthma in the real world. Int J Clin Pract 58 (2004) 592-603
2. Masoli M., Fabian D., Holt S., and Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
3. Barnes P.J. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 109 (2006) 238-245
4. Chung K.F. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533 (2006) 110-117
5. Huang Z., and Mancini J.A. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem 13 (2006) 3253-3262
6. Kroegel C., and Foerster M. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast. Expert Opin Investig Drugs 16 (2007) 109-124
7. Bateman E.D., Izquierdo J.L., Harnest U., et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 96 (2006) 679-686
8. Bousquet J., Aubier M., Sastre J., Izquierdo J.L., et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 61 (2006) 72-78
9. Huang Z., Dias R., Jones T., et al. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem Pharmacol 73 (2007) 1971-1981
10. Santanello N.C., Barber B.L., Reiss T.F., Friedman B.S., Juniper E.F., and Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 10 (1997) 646-651
11. Juniper E.F., Guyatt G.H., Epstein R.S., Ferrie P.J., Jaeschke R., and Hiller T.K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47 (1992) 76-83
12. National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3. Diagnosis and management of asthma (2007), National Institutes of Health NIH Publication Number 08-5846
13. Shields M.D., Brown V., Stevenson E.C., et al. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clin Exp Allergy 29 (1999) 1382-1389
14. Virchow J.C., Oehling A., Boer L., et al. Pulmonary function, activated T cells, peripheral blood eosinophilia, and serum activity for eosinophil survival in vitro: a longitudinal study in bronchial asthma. J Allergy Clin Immunol 94 (1994) 240-249
15. Berry M.A., Hargadon B., Shelley M., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 (2006) 697-708
16. Mukhopadhyay S., Hoidal J.R., and Mukherjee T.K. Role of TNFalpha in pulmonary pathophysiology. Respir Res 7 (2006) 125
17. Brown J.L., Behndig A.F., Sekerel B.E., et al. Lower airways inflammation in allergic rhinitics: a comparison with asthmatics and normal controls. Clin Exp Allergy 37 (2007) 688-695
18. Amon A., Pahl A., and Szelenyi I. Are there any realistic chances to develop new drugs for asthma?. Drug News Perspect 19 (2006) 189-200